FDA approves first treatment for eosinophilic esophagitis in the US
The FDA has granted approval for dupilumab for the treatment of eosinophilic esophagitis for adult and pediatric patients aged 12 years and older, according to a press release.Dupilumab (Dupixent, Regeneron Pharmaceuticals, Inc.) is the first drug in the U.S. specifically indicated for the treatment of this condition.“It is very exciting that we now have the first FDA-approved treatment option specifically for patients with eosinophilic esophagitis, and one that is targeted to an underlying cause of this disease,” Evan Dellon, MD, professor of medicine in the divisionRead More
